Skip to main content
. 2020 Apr 28;11(17):1478–1492. doi: 10.18632/oncotarget.27539

Figure 2. PIM kinase inhibition phenocopies effects of abemaciclib on mTOR signaling.

Figure 2

(A) DMS-53 cells were treated with the indicated concentrations of abemaciclib, palbociclib, or PIM inhibitors PIM447 or AZD1208 for 4 h and analyzed by western blot. (B) DMS-53 cells were transfected with PIM1, PIM2, PIM3, PIM1+PIM2+PIM3, or non-targeting control (NT) siRNA for 48 h and analyzed by western blot. (C) DMS-53 cells were treated with the indicated concentrations of abemaciclib or two additional CDK4/6 inhibitors for 4 h and analyzed by western blot.